CYP26A1: A Drug Target and Biomarker for Drug Metabolism and Response

Target Name: CYP26A1

NCBI ID: G1592

CYP26A1

CYP26A1: A Drug Target and Biomarker for Drug Metabolism and Response

CYP26A1, a cytochrome P450 enzyme, is a drug target and a biomarker that has been extensively studied in the context of drug metabolism and drug response. This gene is located on chromosome 19 and encodes a 47kDa protein that is expressed in various tissues and organs, including the liver, kidney, and brain. CYP26A1 is a key enzyme in the cytochrome P450 (CYP) gene family, which is responsible for the metabolism of a wide variety of drugs, including drugs used for both therapeutic and recreational purposes.

CYP26A1 is a potent enzyme that is expressed in the liver and other organs and is involved in the metabolism of a wide variety of drugs. It is a strong candidate for drug targets because of its central role in drug metabolism and its expression in multiple tissues. Studies have shown that changes in the expression or activity of CYP26A1 can have a significant impact on drug metabolism and drug response. For example, studies have shown that individuals with certain genetic variations in the CYP26A1 gene have altered drug metabolism and increased risk of developing drug -related adverse effects.

In addition to its role in drug metabolism, CYP26A1 is also a potential biomarker for drug response. The expression of CYP26A1 has been shown to be closely associated with drug response, and changes in its expression or activity have been observed in response to various types of drugs. For example, studies have shown that the expression of CYP26A1 is increased in individuals who take statins, a common type of cholesterol-lowering drug, and that its activity is altered in response to changes in cholesterol levels.

Another potential application of CYP26A1 as a biomarker is its role in predicting drug interactions. The CYP26A1 gene is involved in the metabolism of many drugs and is a key determinant of drug metabolism variability. Therefore, changes in the expression or activity of CYP26A1 can have a significant impact on drug interactions. Studies have shown that individuals with certain genetic variations in the CYP26A1 gene have altered drug metabolism and increased risk of developing drug-related adverse effects. Therefore, it can be used as a biomarker to identify potential drug interactions and to predict the outcomes of drug therapy.

In conclusion, CYP26A1 is a drug target and a biomarker that has been extensively studied in the context of drug metabolism and drug response. Its central role in drug metabolism and its expression in multiple tissues make it an attractive target for drug development. Furthermore, its central role in drug metabolism and its expression in multiple tissues make it an attractive target for drug development. potential as a biomarker for drug response and interactions make it an important tool in the development of drug therapy.

Protein Name: Cytochrome P450 Family 26 Subfamily A Member 1

Functions: A cytochrome P450 monooxygenase involved in the metabolism of all-trans retinoic acid (atRA), a signaling molecule that binds to retinoic acid receptors and regulates gene transcription. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase). Catalyzes the hydroxylation of carbon hydrogen bonds of atRA primarily at C-4 and C-18. Has no activity toward 9-cis and 13-cis retinoic acid stereoisomers (PubMed:22020119, PubMed:9228017, PubMed:9716180). May play a role in the oxidative metabolism of xenobiotics such as tazarotenic acid (PubMed:26937021)

The "CYP26A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP26A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets